The Search for Medications to Treat Stimulant Dependence

Progress in understanding the neurobiology of stimulant dependence has enabled researchers to identify medications whose pharmacological effects suggest that they might help patients initiate abstinence or avoid relapse. Several of these medications and a vaccine have shown encouraging results in controlled clinical trials with cocaine-dependent patients. The search for a medical treatment for methamphetamine dependence started more recently, due to the later emergence of this epidemic, but at least one candidate medication has shown promise in early clinical testing. Treatment approaches that combine efficacious medications and empirically proven behavioral interventions, such as voucher-based reinforcement therapy, will almost certainly produce the best results.

Kyle M. Kampman, M.D.
University of Pennsylvania School of Medicine and Treatment Research Center Philadelphia, Pennsylvania

The demand for treatment for cocaine dependence remained roughly level from 1992 to 2005, while the demand for treatment for amphetamine dependence increased about eight-fold (Substance Abuse and Mental Health Services Administration, 2006). Although progress has been made in developing new psychosocial treatments for stimulant dependence, many patients do not substantially benefit from psychotherapy alone. Dropout rates in cocaine dependence treatment programs frequently exceed 50 percent (Alterman et al., 1996). Thus, the identification of medications to augment psychosocial treatment is an urgent research priority. Progress in understanding the neurobiology of stimulant dependence has led to the identification of several medications whose effects counter or alleviate the disordered processing that underlies patients’ symptoms. Depending on their specific actions, these medications may help patients attain an initial period of abstinence or avoid relapse (Table 1). Although none has yet been approved for treating stimulant dependence, several have shown encouraging results in controlled clinical trials.

ABSTINENCE INITIATION

Cocaine withdrawal symptoms, including dysphoric mood, fatigue, sleep disturbance, appetite changes, and irritability, contribute to many dependent patients’ difficulties quitting the drug. Several studies have demonstrated that patients who experience severe cocaine withdrawal symptoms, as measured by the Cocaine Selective Severity Assessment (CSSA), are twice as likely to drop out of treatment and less likely to attain abstinence in outpatient programs (Kampman et al., 2001).
An apparent clinical basis for these associations is that patients who are subject to severe symptoms may keep taking the drug to avoid them. Investigators also have noted that these individuals report more intense highs from experimentally administered cocaine (Sofuoglu et al., 2003; Figure 1) and therefore may experience greater drive to keep taking it.

**Modafinil**

The most promising medication for abstinence initiation is modafinil, a medication currently approved for the treatment of narcolepsy. Modafinil has several characteristics that might facilitate abstinence from cocaine. As a mild stimulant, it may reduce cocaine withdrawal symptoms (Dackis and O’Brien, 2003). As an enhancer of glutamate neurotransmission, it may ameliorate the glutamate depletion seen in chronic cocaine users (Dackis and O’Brien, 2003); improved baseline glutamatergic tone in the nucleus accumbens prevented reinstatement of cocaine self-administration in an animal model of relapse (Baker et al., 2003).

Modafinil has been shown to block the euphoric effects of cocaine in three independent human laboratory studies. In the first, pretreatment with 400 mg of modafinil blunted euphoria from a subsequent intravenous dose of cocaine (30 mg) when compared with pretreatment with 200 mg of modafinil or placebo (Dackis et al., 2003). In a similar study, patients given 400 or 800 mg of modafinil reported lower ratings of “high,” “any drug effect,” and “worth in dollars” in response to a subsequent dose of cocaine, compared with patients who received cocaine alone (Malcolm et al., 2006). Most recently, Hart and colleagues (2008) evaluated the effect of modafinil maintenance (200 or 400 mg/day) on eight non-treatment-seeking cocaine-dependent individuals’ responses to smoked cocaine (at 0, 12, 25, and 50 mg). Modafinil at both dosages attenuated the participants’ frequency of self-administration, subjective ratings of cocaine’s effects, and cocaine-related increases in heart rate and blood pressure.
Modafinil improved cocaine abstinence rates in two clinical trials. In a double-blind pilot trial with 62 cocaine-dependent patients, those who received modafinil submitted more cocaine-metabolite-free urine samples than placebo-treated patients (42 vs. 22 percent; Dackis et al., 2005). Modafinil-treated patients were also deemed more improved on the clinician-rated portion of the Clinical Global Impression Scale (CGIS). The results of the pilot trial were replicated in a recent multicenter trial. Over 16 weeks, 210 cocaine-dependent patients took 200 mg of modafinil daily, 400 mg of modafinil daily, or placebo. Among patients who were dependent only on cocaine, both dosages of modafinil were superior to placebo for promoting abstinence (Dackis, 2007). This trial also included patients (41 percent) who were dually dependent on cocaine and alcohol; their abstinence rates were not increased by modafinil. Two more large-scale double-blind, placebo-controlled clinical trials of modafinil are ongoing.

Modafinil promotes wakefulness and may cause insomnia. Clinicians are advised to avoid its use in patients with bipolar disorder or psychosis, as it may exacerbate symptoms of mania and psychosis. Nor should it be used in patients with left ventricular hypertrophy or mitral valve prolapse, as patients with these conditions developed potentially serious adverse effects in clinical trials.

Propranolol

The beta blocker propranolol has shown promise for the treatment of patients with severe cocaine withdrawal symptoms. Beta blockers are used primarily to treat angina and hypertension, but their primary pharmacological effect—reducing the impact of the neurotransmitter adrenaline—also reduces anxiety. The distressing anxiety and agitation experienced by cocaine-dependent patients during withdrawal appears to be due to heightened sensitivity to the effects of adrenaline and noradrenaline. For example, McDougle and colleagues (1994) demonstrated that giving cocaine-dependent patients yohimbine, a compound that increases adrenaline in the central nervous system, provoked significantly more anxiety during cocaine withdrawal. Along with potential efficacy against withdrawal-related anxiety, propranolol may lessen some of cocaine’s rewarding properties and more uncomfortable symptoms of craving. In a human laboratory trial, the beta blocker carvedilol reduced cocaine self-administration in non-treatment-seeking cocaine-dependent subjects (Sofuoglu et al., 2000).

Three clinical trials have suggested that propranolol may help patients with severe cocaine addiction to remain in treatment and to establish initial abstinence. In the first, a pilot trial in which participants knew what medication they were receiving, propranolol proved safe and was well-tolerated (Kampman et al., 1999). Compared with a historical control group, more propranolol-treated patients (80 vs. 47 percent) stayed in treatment throughout a 7-week outpatient program. In a subsequent double-blind, placebo-controlled trial, propranolol improved treatment retention and decreased cocaine use among 108 patients with severe cocaine withdrawal symptoms, as determined by a score of 27 or more on the CSSA (Kampman et al., 2001). In the most recent trial, propranolol appeared to promote abstinence from cocaine in a trial of 199 patients who entered treatment with severe cocaine withdrawal symptoms (Kampman et al., 2006). Among patients adherent to the study medications, about 24 percent of the propranolol-treated patients were abstinent from cocaine at week 10, as opposed to only 12.5 percent of placebo-treated patients.

Propranolol is usually well-tolerated. The main side effect is sedation. However, beta blockers are best avoided in patients with a history of cocaine-induced cardiac ischemia. Patients who have presented to a medical facility with complaints of chest pain associated with cocaine use have been excluded from all clinical trials of propranolol for cocaine dependence and should not be treated with propranolol.
RELAPSE PREVENTION

Once cocaine-dependent patients have attained a period of abstinence, a more difficult phase of treatment, relapse prevention, begins. Pharmacological strategies for relapse prevention aim to block cocaine-induced euphoria or reduce cocaine craving. New insights into the effects of cocaine on the brain reward system have led to the identification of several promising medications.

Cocaine causes euphoria and reinforcement by raising dopamine levels in the mesocortical reward system. One potential way to counterbalance this effect is to elevate mesocortical levels of gamma-aminobutyric acid (GABA), a neurotransmitter that pushes dopamine levels downward by inhibiting the activity of dopaminergic (dopamine-releasing) neurons. Preclinical trials have suggested that GABAergic compounds (i.e., compounds that promote GABA release or conservation) blunt the dopamine response to cocaine administration and conditioned reminders of prior cocaine use (Dewey et al., 1997) and reduce self-administration of cocaine in animal models (Kushner, Dewey, and Kornetsky, 1999). Accordingly, GABAergic medications are being tested as potential agents to prevent relapse by blocking cocaine-induced euphoria or reducing cue-induced craving caused by reminders of prior cocaine use. Some promising GABAergic medications include gamma-vinyl GABA (GVG), tiagabine, and topiramate.

Gamma-Vinyl GABA

GVG is an antiepileptic that elevates brain GABA concentrations by inhibiting an enzyme, GABA transaminase, that breaks down the neurotransmitter. In preclinical trials, GVG has reduced rodents' self-administration of cocaine (Kushner, Dewey, and Kornetsky, 1999), amphetamine, and methamphetamine (Gerasimov et al., 1999).

GVG has demonstrated potential efficacy for the treatment of stimulant dependence in the two clinical trials, both open-label, that have addressed this question to date. Eight of 20 patients completed the first trial and reported drug-free periods ranging from 46 to 58 days (Brodie, Figuero, and Dewey, 2003). Eighteen of 30 subjects completed the second trial; 16 of the completers submitted drug tests negative for amphetamine and cocaine throughout the last 6 weeks of the trial (Brodie et al., 2005).

Although GVG is used in many countries, it has not been approved for use in the United States because of an association with visual field defects. Data suggest that this adverse effect occurs only after relatively long-term exposure, so brief treatments may be conducted safely (Schmitz et al., 2002). As a precaution, investigators in the second clinical trial of GVG for stimulant dependence used perimetry to assess for potential visual field defects; none occurred (Fechtnner et al., 2006).

Although GVG is grouped here with medications to prevent relapse, it might be considered for abstinence initiation as well. The clinical trials cited earlier were conducted in patients who had not achieved sustained abstinence. Large-scale, well-controlled trials of GVG for both cocaine and amphetamine dependence are planned.

Topiramate

The pharmacological effects of topiramate appear particularly well-suited for preventing relapse to cocaine use. In addition to increasing cerebral levels of GABA and facilitating GABA neurotransmission (Kuzniecky et al., 1998), topiramate weakens the action of glutamate, a neurotransmitter that opposes GABA's potentially therapeutic reduction of dopamine activity. Topiramate's exact mechanisms of action on GABA are not fully understood, but it is known to inhibit glutamate neurotransmission by blocking alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors (Gibbs et al., 2000). In animal models of cocaine relapse, blockade of AMPA receptors in the nucleus accumbens prevented reinstatement of cocaine self-administration (Cornish and Kalivas, 2000).

In a 13-week, double-blind, placebo-controlled pilot trial of topiramate involving 40 cocaine-dependent patients, those who received topiramate were more likely than controls who received placebo to be abstinent during the last 5 weeks of treatment (Kampman et al., 2004). Among patients who returned for at least one visit after receiving medications, more of those on topiramate achieved at least 3 weeks of continuous abstinence (59 vs. 26 percent), and more in this group were rated very much improved on the CGIS at their last visit (71 vs. 32 percent; Kampman et al., 2004).

Topiramate can cause sedation and memory problems, especially if the dose is titrated rapidly. Prescribing criteria contraindicate its use in patients with a history of kidney stones. Drug blood levels of patients with reduced renal function should be monitored, as the drug is excreted by the kidneys. Rare but serious complications of topiramate include metabolic acidosis, acute glaucoma, and oligohydrosis (decreased sweating).
Tiagabine
Tiagabine, a medication currently approved for treatment of seizures, raises brain GABA levels by selectively blocking the presynaptic GABA reuptake transporter type 1. Tiagabine was found to be well-tolerated and moderately effective for improving abstinence in a pilot study with 45 cocaine- and opiate-dependent patients participating in a methadone maintenance program (Gonzalez et al., 2003). In this 10-week trial, the number of urine samples free of cocaine metabolite increased by 33 percent in a group treated with 24 mg of tiagabine daily, while decreasing by 14 percent in a placebo-treated group.

Disulfiram
Disulfiram (Antabuse), a medication that is familiar to substance abuse clinicians as a treatment for alcohol dependence, is a promising cocaine relapse prevention medication with a unique mechanism of action. Disulfiram blocks the enzymatic degradation of cocaine and dopamine, leading to extremely high cocaine and dopamine levels when cocaine is ingested (McCance-Katz, Kosten, and Jatlow, 1998). However, rather than increase the cocaine-induced high, as one might expect, this effect makes the high less pleasant by increasing the associated anxiety. Four published trials have demonstrated that disulfiram reduces cocaine use in cocaine-dependent patients: Carroll et al., 1998 (cocaine- and alcohol-dependent patients); Carroll et al., 2004 (patients dependent on cocaine only); George et al., 2000 (cocaine- and opiate-dependent patients); Petrakis et al., 2000 (cocaine- and opiate-dependent patients).

Disulfiram is generally well-tolerated, although it may cause side effects, including sedation, headache, or a metallic taste in the mouth. If disulfiram is eventually approved for treating cocaine dependence, patients will need to be educated about its effects on cocaine metabolism and the potential danger of using disulfiram and the drug together. Patients also should be told that they may experience an unpleasant reaction (caused by the medication's blockade of an enzyme, aldehyde dehydrogenase, and consequent buildup of acetaldehyde) if they drink alcohol. Disulfiram is contraindicated in patients who have severe myocardial disease or coronary occlusion; who have psychoses; and those who are receiving or those who have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing products.

TA-CD Vaccine
Another promising relapse prevention therapy currently being explored is a vaccine. TA-CD works by stimulating the production of cocaine-specific antibodies that bind to cocaine molecules and prevent them from crossing the blood–brain barrier, thereby blunting the drug's euphoric and reinforcing effects. In laboratory trials, TA-CD decreased rodents' self-administration of cocaine (Kantak et al., 2000).

The vaccine has shown promise in human trials. In one of the first, TA-CD was administered to 34 cocaine-dependent inpatients. A series of three vaccinations resulted in high antibody titers, and the vaccine was well-tolerated (Kosten et al., 2002). More recently, two doses of TA-CD were tested in cocaine-dependent patients in a 12-week outpatient treatment program. Preliminary outcome data suggested that the vaccine reduced the euphoric effects of cocaine; the higher dose was associated with more cocaine abstinence compared with the lower dose (Martell et al., 2005).

MEDICATIONS FOR AMPHETAMINE DEPENDENCE
The search for medications to treat amphetamine and methamphetamine dependence started much more recently than that for cocaine treatment medications. Consequently, fewer medications have been tested. Similarities between the mechanisms of action of amphetamine and methamphetamine and those of cocaine suggest that the same medications may help with both dependencies. Hence, several of the medications that have been discussed are undergoing, or about to undergo, testing for methamphetamine dependence. For instance, trials of topiramate and modafinil are planned.

Bupropion is an antidepressant medication that is also effective in smoking cessation. Bupropion's efficacy for these uses rests upon its ability to support positive mood by inhibiting the reuptake of dopamine into cells, leaving more of the neurotransmitter circulating in the mesolimbic system. The same mechanism may be helpful in easing the negative mood symptoms of methamphetamine withdrawal.

Although studies have shown bupropion to be ineffective in treating cocaine dependence, a recent clinical trial suggested that it may have promise for methamphetamine dependence. Among 151 methamphetamine-dependent patients, bupropion recipients had somewhat better abstinence outcomes compared with placebo recipients; the difference approached, but did
not quite achieve, statistical significance. In a subgroup of patients whose methamphetamine use at baseline was less intensive, however, bupropion treatment was associated with significantly more weeks of abstinence (Elkashef et al., 2007).

Bupropion is fairly well-tolerated. Common side effects include insomnia, agitation, dry mouth, and nausea. This medication is contraindicated in patients with seizure disorders, current or prior diagnoses of bulimia or anorexia nervosa, or concurrent treatment with (or within 14 days of discontinuation of) monoamine oxidase inhibitors. Bupropion should not be used in patients detoxifying from alcohol or sedatives.

MEDICATIONS AND VOUCHER-BASED REINFORCEMENT THERAPY

Voucher-based reinforcement therapy (VBRT) is a behavioral treatment in which substance-dependent patients who achieve predetermined therapeutic goals receive vouchers redeemable for goods and services in the community. VBRT has been shown to be highly effective for helping cocaine-dependent patients achieve initial abstinence (Higgins et al., 1994). Several recent trials have indicated that VBRT may be a highly effective psychosocial treatment platform for enhancing the efficacy of medications for the treatment of cocaine dependence. For example, Kosten and colleagues (2003) gave desipramine, an antidepressant, or placebo with VBRT or a noncontingent voucher control to cocaine- and opiate-dependent patients who were being maintained on buprenorphine. The patients given either desipramine or VBRT increased their frequency of urine samples containing no abused drug more rapidly than patients given neither, and those treated with both desipramine and VBRT produced the most such samples of any group (Kosten et al., 2003). These findings contrast with those of trials in the 1980s, which demonstrated that desipramine in combination with standard psychosocial treatment was ineffective in this population.

In another double-blind trial, bupropion plus VBRT was found to be superior to bupropion or VBRT alone, or placebo, in promoting abstinence from cocaine (Poling et al., 2006). Similar results were reported for the combination of the serotonin reuptake inhibitor (SRI) citalopram and VBRT (Moeller et al., 2007). Like desipramine, SRIs have not been found to be consistently efficacious for the treatment of cocaine dependence when used in association with standard psychosocial treatment.

The best way to integrate effective medications and psychotherapies into a comprehensive plan for the treatment of stimulant dependence has yet to be determined. One can imagine a treatment course that begins with an abstinence initiation medication and contingency management, then switches to relapse prevention medications when the patient reaches some significant abstinence milestone. Alternatively, a patient might continue to receive an abstinence initiation medication that is at some point supplemented with either a relapse prevention medication that is slowly titrated upward or with TA-CD immunization. How long medication treatment should be continued is another unanswered question. Studies to address these questions are being considered, but, for now, there are no data.

CONCLUSIONS

Currently, no medications are approved by the Food and Drug Administration for the treatment of stimulant dependence. However, recent advances in understanding the processes involved in cocaine addiction have allowed researchers to identify several promising candidates (Table 2). Many of these medications have already shown promise in double-blind, placebo-controlled clinical trials, and virtually all of them are undergoing confirmatory testing. Behavioral and psychosocial treatments, especially VBRT, may augment the efficacy of medication for the treatment of stimulant dependence.

Clinicians should be aware that all of the trials to date have been relatively small; therefore, the efficacy and safety of these medications have not been established definitively. In addition, most of the trials have included primarily men; thus, efficacy in women is even less well-established. Although no medications are currently proven to be effective, it is hoped that effective pharmacological treatments for stimulant dependence will soon become available.

CORRESPONDENCE

Kyle M. Kampman, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104; e-mail: kampman_k@mail.trc.upenn.edu.
TABLE 2. Summary of Controlled Clinical Trials of Medications for Cocaine and Methamphetamine Dependence

| MEDICATION, DAILY DOSE, AND OTHER TREATMENTS | N  | DURATION, WEEKS | DEPENDENCE DIAGNOSIS | OUTCOME | REFERENCE |
|----------------------------------------------|----|----------------|----------------------|---------|-----------|
| Modafinil 400 mg vs. placebo                  | 62 | 8              | Cocaine-dependent    | Cocaine-negative urine drug screens were significantly higher in the modafinil group than in the placebo group (42 vs. 22 percent). | Dackis et al., 2005 |
| Propranolol 100 mg vs. placebo                | 108| 8              | Cocaine-dependent with severe cocaine withdrawal symptoms | Among patients who entered treatment with more severe cocaine withdrawal symptoms, mean urinary benzoylecgonine levels were lower in propranolol-treated patients than in placebo-treated patients. | Kampman et al., 2001 |
| Propranolol 100 mg vs. placebo                | 199| 10             | Cocaine-dependent with severe cocaine withdrawal symptoms | The odds of cocaine abstinence, determined by thrice-weekly urine drug screens, improved significantly over time in propranolol-treated patients but not in placebo-treated patients. This effect was most prominent in patients who took at least 80 percent of the prescribed study medication. | Kampman et al., 2006 |
| GVG 2 g (open label)                          | 20 | 9              | Cocaine- or methamphetamine-dependent | Eight of 20 subjects completed the trial and self-reported periods of abstinence ranging from 46 to 58 days. | Brodie, Figuero, and Dewey, 2003 |
| GVG 2 g (open label)                          | 30 | 9              | Cocaine- or methamphetamine-dependent | Of the 18 subjects who completed the trial, 16 submitted drug tests negative for amphetamine and cocaine over the last 6 weeks of the trial. | Brodie et al., 2005 |
| Topiramate 200 mg vs. placebo                 | 40 | 13             | Cocaine-dependent    | Measured by twice-weekly urine drug screens, the likelihood of abstinence after week 8 was significantly greater in topiramate-treated patients than in placebo-treated patients. | Kampman et al., 2004 |
| Tiagabine 12 or 24 mg vs. placebo             | 45 | 10             | Cocaine- and opiate-dependent, maintained on methadone | During weeks 9 and 10, cocaine-free urine samples increased from baseline by 33 percent in the group taking 24 mg of tiagabine, increased by 14 percent in the group taking 12 mg of tiagabine, and decreased by 10 percent in the placebo group. | Gonzalez et al., 2003 |
| Disulfiram 250-500 mg vs. psychotherapy control | 122| 12             | Cocaine and alcohol abusers | Disulfiram treatment was associated with more consecutive weeks of abstinence than was psychotherapy alone. | Carroll et al., 1998 |
| Disulfiram 250 mg vs. placebo                 | 20 | 12             | Cocaine- and opiate-dependent, maintained on buprenorphine | The total number of weeks of cocaine abstinence, verified by thrice-weekly urine drug screens, was significantly higher in disulfiram-treated patients than in placebo-treated patients (7.8 vs. 3.3). | George et al., 2000 |
| Disulfiram 250 mg vs. placebo                 | 67 | 12             | Cocaine- and opiate-dependent, maintained on methadone | Self-reported cocaine and alcohol use was significantly lower in disulfiram-treated patients than in placebo-treated patients. | Petrakis et al., 2000 |
| Disulfiram 250 mg vs. placebo                 | 121| 12             | Cocaine-dependent    | Self-reported cocaine use was significantly lower in disulfiram-treated patients than in placebo-treated patients. The disulfiram-treated group was significantly more likely to submit a cocaine-negative urine drug screen. | Carroll et al., 2004 |
| TA-CD 400 µg vs. TA-CD 2,000 µg               | 18 | 14             | Cocaine-dependent    | The group administered 2,000 µg of TA-CD was significantly more likely to maintain cocaine-free urine samples than the group administered 400 µg. | Martell et al., 2005 |
| Bupropion 300 mg vs. placebo                  | 151| 12             | Methamphetamine-dependent | Among patients who used methamphetamine 18 days or less in the 30 days prior to the trial, significantly more bupropion-treated patients had a methamphetamine-free week (56 percent) than placebo-treated patients (40 percent), based on urine drug screen results. | Elkashef et al., 2007 |
| Desipramine 150 mg + VBRT-C vs. VBRT-C alone vs. desipramine 150 mg + NCV vs. placebo + NCV | 160| 12             | Cocaine- and opiate-dependent, maintained on methadone | The group receiving voucher-based reinforcement and desipramine had more drug-free urine samples (50 percent) than the other three groups (25-25 percent). | Kosten et al., 2005 |
| Bupropion 300 mg + VBRT-CO vs. VBRT-CO alone vs. bupropion 300 mg + NCV vs. placebo + NCV | 106| 25             | Cocaine- and opiate-dependent, maintained on methadone | Patients receiving voucher-based reinforcement and bupropion had significantly fewer cocaine-positive urine drug screens than the other three groups. | Poling et al., 2006 |
| Citalopram 20 mg + VBRT-C vs. placebo + VBRT-C | 76 | 12             | Cocaine-dependent    | Citalopram-treated patients had a significantly lower probability of submitting a cocaine-positive urine sample than the placebo-treated patients. | Moeller et al., 2007 |
REFERENCES

Alterman, A.I., et al., 1996. Prediction of attrition from day hospital treatment in lower socioeconomic cocaine-dependent men. Drug and Alcohol Dependence 42(3):227-233.

Baker, D.A., et al., 2003. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature Neuroscience 6(7):743-749.

Brodie, J.D., et al., 2005. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 55(2):122-125.

Brodie, J.D.; Figuero, E.; and Dewey, S.L., 2003. Treating cocaine addiction: From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 50(3):261-265.

Carroll, K.M., et al., 1998. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93(5):713-727.

Carroll, K.M., et al., 2004. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry 61(3):264-272.

Cornish, J.L. and Kalivas, P.W., 2000. Glutamatergic transmission in the nucleus accumbens mediates relapse in cocaine addiction. Journal of Neuroscience 20(2):731-739.

Dackis, C.A., 2007. Modafinil for cocaine dependence. Paper presented at the American Society of Addiction Medicine, Medical Scientific Conference, Miami, FL.

Dackis, C.A., et al., 2003. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 70(1):29-37.

Dackis, C.A., et al., 2005. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30(1):205-211.

Dackis, C.A., and O’Brien, C., 2003. Glutamatergic agents for cocaine dependence. Annals of the New York Academy of Sciences 1003:328-345.

Dewey, S.L., et al., 1997. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 25(4):393-398.

Elkashef, A.M., et al., 2008. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33(5):1162-1170.

Feichtner, R.D., et al., 2006. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results. Archives of Ophthalmology 124(9):1257-1262.

George, T.P., et al., 2000. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry 47(12):1080-1086.

Gerasimov, M.R., et al., 1999. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 34(1):11-19.

Gibbs, J.W., et al., 2000. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl. 1):S10-S16.

Gonzalez, G., et al., 2003. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction 98(11):1625-1632.

Hart, C.L., et al., 2008. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33(4):261-265.

Higgins, S.T., et al., 1994. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Archives of General Psychiatry 51(7):568-576.

Kampman, K.M., et al., 1997. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 129(4):279-284.

Kushner, S.A.; Dewey, S.L.; and Kornetsky, C., 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 290(2):797-802.

Kuzniecky, R., et al., 1998. Topiramate increases cerebral GABA in healthy humans. Neurology 51(2):627-629.

Malcolm, R., et al., 2006. Modafinil and cocaine interactions. Neuropsychopharmacology 31(4):577-587.

Martell, B.A., et al., 2005. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 57(2):129-137.

Kantak, K.M., et al., 2000. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 95(1):50-58.

Kosten, T., et al., 2002. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 20(7-8):1196-1204.

Kosten, T., et al., 2003. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine-maintained patients. Drug and Alcohol Dependence 70(3):315-320.

Kushner, S.A.; Dewey, S.L.; and Kornetsky, C., 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 290(2):797-802.

Kuzniecky, R., et al., 1998. Topiramate increases cerebral GABA in healthy humans. Neurology 51(2):627-629.

Malcolm, R., et al., 2006. Modafinil and cocaine interactions. American Journal of Drug and Alcohol Abuse 32(4):577-587.

Martell, B.A., et al., 2005. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 57(2):129-137.

McCance-Katz, E.; Kosten, T.R.; and Jatlow, P., 1998. Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence 52(1):27-39.

McDougle, C.J., et al., 1998. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Archives of General Psychiatry 55(9):713-719.

Moeller, F.G., et al., 2007. Citalopram combined with behavioral treatment reduces cocaine use: A double-blind, placebo-controlled trial. American Journal on Drug and Alcohol Abuse 33(3):367-378.

Petrasik, I.L., et al., 2000. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95(2):219-228.

Poling, J., et al., 2006. Six-month trial of buproprion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 63(2):219-228.

Schmitz, B., et al., 2002. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study. Journal of Neurology 249(4):469-475.

Sofuoglu, M.; Kornetsky, C.; and Kornetsky, C., 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 290(2):797-802.

Kuzniecky, R., et al., 1998. Topiramate increases cerebral GABA in healthy humans. Neurology 51(2):627-629.

Malcolm, R., et al., 2006. Modafinil and cocaine interactions. American Journal of Drug and Alcohol Abuse 32(4):577-587.

Martell, B.A., et al., 2005. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 57(2):129-137.

McCance-Katz, E.; Kosten, T.R.; and Jatlow, P., 1998. Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence 52(1):27-39.

McDougle, C.J., et al., 1998. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Archives of General Psychiatry 55(9):713-719.

Moeller, F.G., et al., 2007. Citalopram combined with behavioral treatment reduces cocaine use: A double-blind, placebo-controlled trial. American Journal on Drug and Alcohol Abuse 33(3):367-378.

Petrasik, I.L., et al., 2000. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95(2):219-228.

Poling, J., et al., 2006. Six-month trial of buproprion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 63(2):219-228.

Schmitz, B., et al., 2002. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study. Journal of Neurology 249(4):469-475.

Sofuoglu, M.; Kornetsky, C.; and Kornetsky, C., 1999. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 290(2):797-802.

Kuzniecky, R., et al., 1998. Topiramate increases cerebral GABA in healthy humans. Neurology 51(2):627-629.

Malcolm, R., et al., 2006. Modafinil and cocaine interactions. American Journal of Drug and Alcohol Abuse 32(4):577-587.